Stevens-Johnson syndrome and toxic epidermal necrolysis induced by amifostine during head and neck radiotherapy

Laurence Valeyrie-Allanore; Nicolas Poulalhon; Jean-Paul Fagot; Peggy Sekula; Batya Davidovici; Alexis Sidoroff; Maja Mockenhaupt

doi:10.1016/j.radonc.2008.01.021

Stevens-Johnson syndrome and toxic epidermal necrolysis induced by amifostine during head and neck radiotherapy

Radiother Oncol. 2008 May;87(2):300-3. doi: 10.1016/j.radonc.2008.01.021. Epub 2008 Mar 6.

Authors

Laurence Valeyrie-Allanore¹, Nicolas Poulalhon, Jean-Paul Fagot, Peggy Sekula, Batya Davidovici, Alexis Sidoroff, Maja Mockenhaupt

Affiliation

¹ Department of Dermatology, Université Paris XII, Créteil Cedex, France. laurence.allanore@hmn.aphp.fr

PMID: 18328585
DOI: 10.1016/j.radonc.2008.01.021

Abstract

Amifostine is an organic thiophosphate prodrug used for cytoprotection against toxic effects of radiotherapy and chemotherapy. In a European prospective study of SJS/TEN, six patients were suspected to have SJS/TEN associated with amifostine. Our findings suggest that the risk of life-threatening cutaneous adverse reactions to amifostine could be significantly increased.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Adverse Drug Reaction Reporting Systems
Aged
Amifostine / adverse effects*
Europe
Female
Head and Neck Neoplasms / radiotherapy*
Humans
Male
Middle Aged
Prospective Studies
Radiation-Protective Agents / adverse effects*
Stevens-Johnson Syndrome / chemically induced*
Stevens-Johnson Syndrome / etiology*

Substances

Radiation-Protective Agents
Amifostine